Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Melphalan HCl Conditioning for ASCT in Multiple Myeloma
NCT06425276Phase 4Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of EVOMELA in multiple myeloma (MM), sponsored by CASI Pharmaceuticals, Inc. Primary endpoints: Rate of patients achieving myeloablation at 95 days, Time to achieving myeloablation at 95 days and 4 more. Started Jul 2020; status: completed.
02
Drugs
EVOMELA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06425276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425276.